These 10 Companies Led Tuesday’s Charge

2. Travere Therapeutics Inc. (NASDAQ:TVTX)

Shares of Travere surged by 12.56 percent on Tuesday to close at $23.75 apiece as investors gobbled up shares following plans to submit a supplemental new drug application (NDA) seeking traditional approval of Filspari, a new drug aimed at treating focal segmental glomerulosclerosis (FSGS), a rare kidney disorder. The submission plan followed the successful completion of TVTX’s Type C meeting with the US Food and Drug Administration.

“Treatment options for FSGS are desperately needed as there are currently no approved medicines indicated for this devastating, progressive, and complex rare kidney disorder that affects more than 40,000 adults and children in the US,” said TVTX President and CEO Eric Dube.

TVTX said it plans to submit the NDA around the end of the first quarter of the year. If approved, Filspari could become the first and only medicine to treat FSGS.